MET and digestive system neoplasm: Similarly, as a MET inhibitor, Savolitinib has received NMPA approval for treating NSCLC, but for gastrointestinal tumors (mainly GC and PC), it remains in the phase I clinical stage exploring pharmacokinetic and related properties [335, 336].